AU2013354422B2 - Neurotensin receptor ligands - Google Patents
Neurotensin receptor ligands Download PDFInfo
- Publication number
- AU2013354422B2 AU2013354422B2 AU2013354422A AU2013354422A AU2013354422B2 AU 2013354422 B2 AU2013354422 B2 AU 2013354422B2 AU 2013354422 A AU2013354422 A AU 2013354422A AU 2013354422 A AU2013354422 A AU 2013354422A AU 2013354422 B2 AU2013354422 B2 AU 2013354422B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- group
- acceptor
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KQCPVJHRSLVNEU-UHFFFAOYSA-N CC(C)c1cc(C(N(C)CCCN(C)CCCN(C)C(CCC(NCCCOCCOCCOCCCNC(CNCCN(CCN(CCNCC(O)=O)CC(O)=C)CC(O)=O)=O)=O)=O)=O)ccc1-[n](c(-c(c(OC)ccc1)c1OC)c1)nc1C(NC1(C2CC(C3)CC1CC3C2)C(O)=O)=O Chemical compound CC(C)c1cc(C(N(C)CCCN(C)CCCN(C)C(CCC(NCCCOCCOCCOCCCNC(CNCCN(CCN(CCNCC(O)=O)CC(O)=C)CC(O)=O)=O)=O)=O)=O)ccc1-[n](c(-c(c(OC)ccc1)c1OC)c1)nc1C(NC1(C2CC(C3)CC1CC3C2)C(O)=O)=O KQCPVJHRSLVNEU-UHFFFAOYSA-N 0.000 description 1
- HOOMWAFHEPCPCC-UHFFFAOYSA-N CC(Nc(cc1)ccc1[IH]C(C)=S)=S Chemical compound CC(Nc(cc1)ccc1[IH]C(C)=S)=S HOOMWAFHEPCPCC-UHFFFAOYSA-N 0.000 description 1
- QQWBCSJVJJAUGE-UHFFFAOYSA-N CCN(C(CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O)=C)O Chemical compound CCN(C(CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O)=C)O QQWBCSJVJJAUGE-UHFFFAOYSA-N 0.000 description 1
- FCKYPQBAHLOOJQ-RGURZIINSA-N OC(CN(CC(O)=O)[C@@H](CCCC1)C1N(CC(O)=O)CC(O)=O)=O Chemical compound OC(CN(CC(O)=O)[C@@H](CCCC1)C1N(CC(O)=O)CC(O)=O)=O FCKYPQBAHLOOJQ-RGURZIINSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
| EP12008208.6 | 2012-12-07 | ||
| PCT/EP2013/003700 WO2014086499A1 (en) | 2012-12-07 | 2013-12-06 | Neurotensin receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013354422A1 AU2013354422A1 (en) | 2015-05-28 |
| AU2013354422B2 true AU2013354422B2 (en) | 2018-03-15 |
Family
ID=47355771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013354422A Active AU2013354422B2 (en) | 2012-12-07 | 2013-12-06 | Neurotensin receptor ligands |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10961199B2 (enExample) |
| EP (3) | EP2740726A1 (enExample) |
| JP (2) | JP6576828B2 (enExample) |
| KR (1) | KR102290803B1 (enExample) |
| CN (2) | CN109320502B (enExample) |
| AU (1) | AU2013354422B2 (enExample) |
| BR (1) | BR112015012530B1 (enExample) |
| CA (1) | CA2893605C (enExample) |
| DK (2) | DK2928870T3 (enExample) |
| ES (2) | ES2941629T3 (enExample) |
| FI (1) | FI3712131T3 (enExample) |
| HU (2) | HUE061839T2 (enExample) |
| IL (1) | IL239080B (enExample) |
| MX (1) | MX370354B (enExample) |
| PL (2) | PL3712131T3 (enExample) |
| PT (2) | PT3712131T (enExample) |
| RU (1) | RU2671970C2 (enExample) |
| SG (2) | SG11201503880YA (enExample) |
| WO (1) | WO2014086499A1 (enExample) |
| ZA (1) | ZA201503446B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| WO2015188934A1 (en) * | 2014-06-10 | 2015-12-17 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| JP6810146B2 (ja) | 2015-11-24 | 2021-01-06 | トランスフェール プリュ エス．ウ．セ． | 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート |
| EP3279197A1 (en) * | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| KR102880156B1 (ko) | 2017-07-24 | 2025-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 항cd8 항체 및 이의 용도 |
| HUE070009T2 (hu) | 2019-07-08 | 2025-05-28 | 3B Pharmaceuticals Gmbh | Fibroblaszt aktiváló protein ligandumot tartalmazó vegyületek és alkalmazásuk |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| IL301868A (en) * | 2020-10-22 | 2023-06-01 | Nihon Mediphysics Co Ltd | A method for preparing a radioactive zirconium complex |
| CA3217024A1 (en) * | 2021-04-23 | 2022-10-27 | Fusion Pharmaceuticals Inc. | Methods for treatment of cancers |
| KR20240007257A (ko) * | 2021-05-13 | 2024-01-16 | 더 제너럴 하스피탈 코포레이션 | 알데히드의 생체내 검출을 위한 분자 프로브 |
| EP4355377A4 (en) * | 2021-06-16 | 2025-05-07 | Fusion Pharmaceuticals Inc. | COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL |
| WO2022261770A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| EP4355317A4 (en) * | 2021-06-16 | 2025-04-30 | Fusion Pharmaceuticals Inc. | COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX |
| WO2023141722A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
| CA3243418A1 (en) | 2022-02-18 | 2023-08-24 | Full Life Tech Hk Limited | COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES |
| EP4518912A1 (en) * | 2022-05-03 | 2025-03-12 | The University of North Carolina at Chapel Hill | Development of ntsr targeted agents for imaging and therapy applications |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
| WO2025144920A1 (en) * | 2023-12-28 | 2025-07-03 | Radionetics Oncology, Inc. | Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof |
| WO2025146126A1 (en) * | 2024-01-04 | 2025-07-10 | Full-Life Technologies Hk Limited | Preparation method of compounds targeting neurotensin receptor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996032382A1 (fr) * | 1995-04-11 | 1996-10-17 | Sanofi | 1-phenylpyrazole-3-carboxamides actifs sur les recepteurs de la neurotensine |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| JPH11514329A (ja) | 1994-02-18 | 1999-12-07 | マリンクロット・メディカル・インコーポレイテッド | 標識化ペプチド化合物 |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| WO1996031531A2 (en) | 1995-04-04 | 1996-10-10 | Advanced Bioconcept, Inc. | Fluorescent peptides |
| WO1997004311A2 (en) | 1995-07-20 | 1997-02-06 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| WO1998033531A1 (en) | 1997-02-03 | 1998-08-06 | Mallinckrodt Medical, Inc. | Method for the detection and localization of malignant human tumours |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| AU3485999A (en) | 1998-04-10 | 1999-11-01 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| CA2374270A1 (en) | 1999-06-24 | 2000-12-28 | Ananthachari Srinivasan | Labeled neurotensin derivatives |
| EP2338525A3 (en) * | 2003-07-09 | 2011-08-03 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| CN101626787A (zh) * | 2007-01-19 | 2010-01-13 | 马林克罗特公司 | 诊断的和治疗的环氧合酶-2结合配体 |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| US8487077B2 (en) * | 2008-09-16 | 2013-07-16 | The Regents Of The University Of California | Simplified one-pot synthesis of [18F]SFB for radiolabeling |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| ES2538002T3 (es) * | 2009-01-07 | 2015-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para el tratamiento, la evaluación pronóstica y la detección de cáncer de mama |
| EP2454272B1 (en) | 2009-07-16 | 2017-08-23 | IASON GmbH | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en not_active Ceased
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active Active
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996032382A1 (fr) * | 1995-04-11 | 1996-10-17 | Sanofi | 1-phenylpyrazole-3-carboxamides actifs sur les recepteurs de la neurotensine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013354422B2 (en) | Neurotensin receptor ligands | |
| JP7065567B2 (ja) | ニューロテンシン受容体リガンドを含むコンジュゲートおよびそれらの使用 | |
| Abd-Elgaliel et al. | Design, Synthesis, and Biological Evaluation of an Antagonist− Bombesin Analogue as Targeting Vector | |
| HK40037865B (en) | Neurotensin receptor ligands | |
| KR20250016195A (ko) | 전립선-특이적 막 항원(psma) 리간드 | |
| HK40037865A (en) | Neurotensin receptor ligands | |
| HK1210148B (en) | Neurotensin receptor ligands | |
| HK40003630A (en) | Neurotensin receptor ligands | |
| HK40003630B (en) | Neurotensin receptor ligands | |
| JP4318985B2 (ja) | ソマトスタチンアナログ誘導体およびその利用 | |
| US20250303005A1 (en) | Prostate specific membrane antigen (psma) ligands with improved renal clearance | |
| EP4455159A1 (en) | Gastric inhibitory peptide receptor ligands with bio-distribution modifier | |
| KR20250175337A (ko) | 생체분포 변형제를 갖는 위 억제 펩티드 수용체 리간드 | |
| JP2024542966A (ja) | 胃抑制ペプチドレセプターリガンド | |
| Mascarin | Triazole-based Radiopeptidomimetics: Novel Neurotensin (8-13) Analogues with Increased Metabolic Stability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |